CBLL: Three White Soldiers detected on 12 Aug 2026

A three white soldiers pattern is forming in CBLL following positive Q2 2026 earnings released August 10, showing 33% revenue growth to $28.1 million year-over-year. At $21.31, the stock trades 96.41% above its 52-week low and 12.41% below its 52-week high. Key resistance stands at $21.75 with support at $15.96. The setup scores well on structure (15.0/15) and volume (12.0/12), though breakout scores 10.4/13. Exceptional volume ratio of 4.35x average suggests institutional accumulation supporting the three-white-soldiers formation. Overall pattern quality score of 79.4/98 indicates a high-conviction setup.

Ceribell reported Q2 2026 revenue of $28.1 million, up 33% year-over-year, with earnings released August 10. The company received FDA 510(k) clearances for Epileptiform Abnormality Detection and Artifact Reduction algorithms. In Q1, Ceribell added 33 new hospital accounts, marking its strongest quarter for account growth since going public. The company activated its first sites for a delirium pilot, entering a $1 billion market with the only FDA-cleared diagnostic tool. In early August, Ceribell secured CMS New Technology Add-On Payment (NTAP) for its delirium monitor system. Market context is favorable: healthcare sector shows bullish regime (0.94 score), supporting upside momentum post-earnings.

A successful breakout above resistance at $21.75 would target $22.66 conservatively, representing a 4.3% gain from current price. Historical data suggests the three-white-soldiers pattern offers a 54.74% win probability. Volume confirmation is already strong at 4.35x average, indicating institutional follow-through. Invalidation occurs at key support of $15.96, roughly 25% below current price—a risk/reward ratio of approximately 1:6 favoring bulls. The pattern suggests continuation into the measured move target if resistance breaks decisively on sustained volume.

RSI at 70.8 indicates overbought conditions, risking mean reversion pullback before further upside. Operating expenses jumped 36% year-over-year to $43.9 million in Q1, and the company reported a $19.7 million net loss. Litigation expenses of $5.6 million in Q1 remain a persistent drag on profitability. Consensus 2026 loss estimate increased to -$1.71 per share from -$1.46. Despite strong revenue growth, profitability remains elusive. Recent insider selling activity noted post-earnings adds uncertainty. Stock has surged 19.52% in two weeks; consolidation risk is elevated before continuation higher.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.